The Jedd Wolchok Lab

The overall goals of my laboratory efforts are to develop and implement new ways to use the immune system to treat cancer.

Some of our ongoing projects include:

Investigation of the GITR pathway as it relates to regulatory and effector T cells.
Use of OX40 agonists alone and in combination with chemotherapy.
Exploration of the role of myeloid derived suppressor cells in tumor immunity.
Studying of the mechanisms underlying coordinated regulation of myeloid cells and IDO in the tumor environment and their therapeutic relevance.
Role of CD47 in T cell signaling.
Developing optimal cancer vaccine strategies in pre-clinical mouse models.
Role of exercise in immune checkpoint blockade.

We are also closely aligned with the Ludwig Center for Cancer Immunity and work closely with that group to monitor immune responses in patients receiving experimental immunotherapy treatments.

Jedd D. Wolchok, MD, PhD, FASCO

Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation; Chief, Melanoma and Immunotherapeutics Service; Director, Parker Institute for Cancer Immunotherapy at MSK

Professor

Research Focus

Physician-scientist Jedd Wolchok investigates novel approaches for cancer immunotherapy and mechanisms of tumor cell–immune cell interactions. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring innovative immunotherapeutic strategies in laboratory models and as a principal investigator in numerous pivotal clinical trials.

Education

Princeton University, Princeton, NJ BA
New York University, New York, NY MS
New York University, New York, NY PhD
New York University, New York, NY MD

Clinical Office 646-888-5178
Lab Phone: 646-888-2585 (Laboratory Office)

View Jedd D. Wolchok’s profile.

Lab Members

Jedd D. Wolchok, MD, PhD — Jedd D. Wolchok

Lab Head

Taha Merghoub, PhD — Taha Merghoub

Attending Biologist

Beatrice Yin, MA — Beatrice Yin

Research Lab Manager

Daniel Hirschhorn-Cymerman, PhD — Daniel Hirschhorn-Cymerman

Senior Research Scientist

Sadna Budhu, PhD — Sadna Budhu

Research Associate

Roberta Zappasodi, PhD — Roberta Zappasodi

PICI Bridge Scholar

Hyejin Choi, PhD — Hyejin Choi

Research Associate

Luis Felipe Campesato, PhD — Luis Felipe Campesato

Research Associate

Mathieu Gigoux, PhD — Mathieu Gigoux

Research Fellow

Chien-Huan Weng, PhD — Chien-Huan Weng

Research Fellow

Judith Michels, MD, PhD — Judith Michels

Research Fellow

Levi Mark Bala Mangarin, BS — Levi Mark Bala Mangarin

Bioinformatics Technician

Shakuntala Tiwari

Senior Research Assistant

Pictured: Xia Yang — Xia Yang

Senior Research Technician

Dmitriy Zamarin, MD, PhD — Dmitriy Zamarin

Assistant Attending Physician

Alexander Lesokhin, MD — Alexander Lesokhin

Assistant Member

Pictured: Michael Postow — Michael Postow

Assistant Attending Physician

Margaret K. Callahan, MD, PhD — Margaret K. Callahan

Assistant Attending, Department of Medicine

Danny Khalil

Medical Oncologist

Claire Friedman, MD — Claire Friedman

Medical Oncologist

Bianca Santomasso, MD, PhD — Bianca Santomasso

Neuro-Oncologist

Allison Betof, MD, PhD — Allison Betof

Medical Oncology Fellow

Arnab Ghosh, MBBS, PhD — Arnab Ghosh

Hematology and Medical Oncology Fellow

Andrew Chow, MD, PhD — Andrew Chow

Medical Oncology Fellow

Affiliations

Gerstner Sloan Kettering Graduate School of Biomedical Sciences

Publications

Learn more

Selected Achievements

The use of immunomodulatory antibodies, specifically antibodies which interfere with the CTLA-4 co-inhibitory pathway has been studied in over a dozen clinical trials. Dr. Wolchok led a phase III study of ipilimumab plus dacarbazine in patients with previously untreated metastatic melanoma. Overall survival was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (Wolchok et al, NEJM 30;364(26):2517-26, 2011)